Emmaus Life Sciences, Inc.

Climate Impact & Sustainability Data (2008, 2021)

certain information and data relating to and necessary for the completion of the Registrant's financial statements and management's discussion and analysis of financial condition and results of operations could not be obtained by Registrant within such time period without unreasonable effort or expense.

Launched Endari® Patient Support Program to provide eligible patients access to Endari®

Operated at a loss and may continue to operate at a loss for the foreseeable future.
Dependent on financing to sustain operations; substantial doubt regarding ability to continue as a going concern.
Dependent on commercial success of Endari®; intense competition from companies with greater resources.
Majority of Endari® sales to a few customers; loss of a customer could adversely affect results of operations.
Limited market exclusivity for Endari®; lack of exclusivity in some regions could adversely affect commercial success.
Risks associated with marketing Endari® internationally.
Reliance on third parties for future clinical trials; third parties may not perform satisfactorily.
Product liability exposure relating to Endari®.
Need to increase the size and complexity of the organization; difficulties in managing growth and executing growth strategy.
Historical material weaknesses in internal controls over financial reporting not fully remediated.
Business may be adversely impacted by consequences of Russia's invasion of Ukraine.

Expanding commercialization of Endari® in the U.S. and MENA region.
Implementing changes to internal control over financial reporting (e.g., engaging third-party accounting consultants, enhancing review controls, implementing a new ERP system).
Maintaining product liability insurance coverage.